Brief Report: circRUNX1 as Potential Biomarker for Cancer Recurrence in EGFR Mutation-Positive Surgically Resected NSCLC

Brief Report: circRUNX1 as Potential Biomarker for Cancer Recurrence in EGFR Mutation-Positive Surgically Resected NSCLC

Introduction: As recently evidenced by the ADAURA trial, most patients with stages IB to IIIA of resected EGFR-mutant lung adenocarcinoma benefit from osimertinib as adjuvant therapy. Nevertheless, predictive markers of response and recurrence are still an unmet need for more than 10% of these patie...

Full description

Bibliographic Details
Main Authors: Carlos Pedraz-Valdunciel, PhD, Masaoki Ito, MD, Stavros Giannoukakos, PhD student, Ana Giménez-Capitán, MSc, Miguel Ángel Molina-Vila, PhD, Rafael Rosell, MD, PhD
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:JTO Clinical and Research Reports
Subjects:
CircRUNX1
Biomarker
EGFR mutation
NSCLC
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323001479

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323001479

Similar Items